Bridgeway Capital Management’s vTv Therapeutics VTVT Stock Holding History

Bridgeway Capital Management’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-675	Closed	-$21.8K	–	1451
2023 Q1	$21.8K	Hold	675	–	–	﹤0.01%	1353
2022 Q4	$17.6K	Hold	675	–	–	﹤0.01%	1348
2022 Q3	$26K	Buy	+675	New	+$26.6K	﹤0.01%	1383
2019 Q4	–	Sell	-1,720	Closed	-$107K	–	1392
2019 Q3	$107K	Hold	1,720	–	–	﹤0.01%	1241
2019 Q2	$98K	Hold	1,720	–	–	﹤0.01%	1244
2019 Q1	$118K	Hold	1,720	–	–	﹤0.01%	1270
2018 Q4	$182K	Hold	1,720	–	–	﹤0.01%	1230
2018 Q3	$53K	Hold	1,720	–	–	﹤0.01%	1408
2018 Q2	$106K	Sell	1,720 -155	-8%	-$11.4K	﹤0.01%	1359
2018 Q1	$305K	Hold	1,875	–	–	﹤0.01%	1202
2017 Q4	$451K	Hold	1,875	–	–	﹤0.01%	1122
2017 Q3	$449K	Hold	1,875	–	–	0.01%	1122
2017 Q2	$373K	Hold	1,875	–	–	﹤0.01%	1163
2017 Q1	$491K	Hold	1,875	–	–	0.01%	1079
2016 Q4	$362K	Hold	1,875	–	–	﹤0.01%	1184
2016 Q3	$539K	Hold	1,875	–	–	0.01%	1063
2016 Q2	$435K	Hold	1,875	–	–	0.01%	1101
2016 Q1	$387K	Buy	+1,875	New	+$467K	0.01%	1137

Other funds holding VTVT

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SQA

Simon Quick Advisors Morristown, New Jersey $2.48B AUM 21.26% 1-Year Est. Return

Bridgeway Capital Management's VTVT Position: Q2 2023 in Review

Bridgeway Capital Management sold out of vTv Therapeutics (VTVT) in Q2 2023, closing a stake of 675 shares — an estimated $21.8K sold.

Bridgeway Capital Management first reported a position in VTVT in Q1 2016 and held it in 18 quarters. The position peaked at $539K in Q3 2016. 20 funds tracked by Wall St. Rank hold VTVT as of Q2 2023.

Bridgeway Capital Management reported no remaining vTv Therapeutics position as of Q2 2023 after selling out during the quarter.
Bridgeway Capital Management sold 675 vTv Therapeutics shares in Q2 2023, an estimated $21.8K.
Bridgeway Capital Management first reported a position in vTv Therapeutics in Q1 2016 and held it in 18 quarters.
Bridgeway Capital Management's vTv Therapeutics position peaked at $539K in Q3 2016.
20 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.